RxDoctor Payments Data

David Drucker, MD

Interventional Cardiology · Newtown, PANPI 1730179854

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (42.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 84.7% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $30,951 and has fallen 74.3% since, to $7,952 in 2025.

$83,268in general payments, 2019–2025

Across 310 payments — averaging $268.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$71K
  • Johnson & Johnson$7K
  • Edwards Lifesciences$2K
  • Medtronic$2K
  • AstraZeneca$310
  • E.r. Squibb & Sons, L.L.C.$264
  • plus $2K from 23 others
$2,000in research payments, 2019–2025

Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$2K

What the payments were for

  • Consulting fees$35,05542%
  • Speaking & faculty fees$31,23838%
  • Travel & lodging$7,5599%
  • Food & beverage$9,38411%
  • Education$330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$83,268 in reported general payments places this provider in the 85th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$374,111
Medicare patients
935
Services billed
3,495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban308$396,147
Repatha SureclickEvolocumab124$127,432
EntrestoSacubitril/Valsartan51$73,564
BrilintaTicagrelor53$65,433
FarxigaDapagliflozin Propanediol47$47,580
XareltoRivaroxaban34$43,466
Praluent PenAlirocumab33$23,072
Pitavastatin Calcium29$17,958
Metoprolol Succinate695$12,828
Carvedilol ErCarvedilol Phosphate19$11,273
Rosuvastatin Calcium599$10,725
CrestorRosuvastatin Calcium18$8,342
LivaloPitavastatin Calcium14$7,540
ClopidogrelClopidogrel Bisulfate390$6,868
Atorvastatin Calcium528$6,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$169$396,147308 claims
AstraZenecaBrilinta, Farxiga, Crestor$310$121,356118 claims
NovartisEntresto$94$73,56451 claims
Johnson & JohnsonXarelto$6,818$43,46634 claims
Kowa Pharmaceuticals America, Inc.Livalo$14$7,54014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Newtown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →